Walking economy, as measured by decreased oxygen demand, is improved in multiple sclerosis patients responding to fampridine

被引：0
|
作者：
Riess, K. J. [1 ,2 ]
Stewart, B. J. [3 ]
机构：
[1] Univ Alberta, Northern Alberta Inst Technol, Sch Hlth & Life Sci, Edmonton, AB, Canada
[2] Univ Alberta, Fac Rehabil Med, Edmonton, AB, Canada
[3] Univ Alberta, Div Neurol, Dept Med, Edmonton, AB, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P807
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [31] Cortical modulatory effect of Fampridine in patients with multiple sclerosis and gait impairment
    Ahdab, R.
    Shatila, M.
    Shatila, A.
    Khazen, G.
    Freiha, J.
    Salem, M.
    Makhoul, K.
    Nawwar, R.
    El Nemr, S.
    Ayache, S.
    Riachi, N.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 723 - 724
  • [32] The Role of Fampridine in the Symptomatic Treatment of Gait Impairment in Patients with Multiple Sclerosis
    Piwonski, Michal
    Zak, Klaudia
    Gierszon, Patrycja
    Morawska, Izabela
    Psiuk, Dominika
    Stachura, Agata
    ACTA BALNEOLOGICA, 2019, 61 (03): : 199 - 207
  • [33] QUALITY OF LIFE AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH PROLONGED-RELEASE FAMPRIDINE 10 MG TABLETS FOR WALKING IMPAIRMENT
    Liu, Y.
    McNeill, M.
    Lee, A.
    Zhong, J.
    Mehta, L. R.
    VALUE IN HEALTH, 2014, 17 (07) : A401 - A402
  • [34] How does fampridine change gait kinematics to improve walking speed in primary progressive multiple sclerosis?
    Gonzalez-Suarez, I.
    Montero-Atalaya, A.
    Gomez-Andres, D.
    Pulido-Valdeolivas, I.
    Orviz, A.
    Rodriguez-Andonaegui, I.
    Martin-Gonzalo, J. A.
    Rausell, E.
    Oreja-Guevara, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 195 - 195
  • [35] The impact of fampridine treatment on fatigue, quality of life and mood in patients with multiple sclerosis
    Barros, A.
    Sequeira, J.
    Vaz, S.
    Morgado, J.
    Bras, P.
    Melancia, D.
    Fernandes, A.
    Sousa, A.
    Dias, S.
    Capela, C.
    Pedrosa, R.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 688 - 688
  • [36] Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
    Rodriguez-Leal, Francisco Alejandro
    Haase, Rocco
    Akguen, Katja
    Eisele, Judith
    Proschmann, Undine
    Schultheiss, Thorsten
    Kern, Raimar
    Ziemssen, Tjalf
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10 : 1 - 11
  • [37] Recommendations for the Use of Prolonged-Release Fampridine in Patients with Multiple Sclerosis (MS)
    Preiningerova, Jana Lizrova
    Baumhackl, Ulf
    Csepany, Tunde
    Czaplinski, Adam
    Deisenhammer, Florian
    Derfuss, Tobias
    Fabjan, Tanja H.
    Fazekas, Franz
    Fuchs, Siegrid
    Havrdova, Eva
    Ledinek, Alenka Horvath
    Illes, Zsolt
    Jazbec, Sasa Sega
    Klimova, Eleonora
    Komoly, Samuel
    Kurca, Egon
    Linnebank, Michael
    Lisy, Lubomir
    Mares, Jan
    Prochazkova, Lubica
    Csilla, Rozsa
    Szilasiova, Jarmila
    Stourac, Pavel
    Talab, Radomir
    Turcani, Peter
    Vachova, Marta
    Vecsei, Laszlo
    Vodusek, David
    Zapletalova, Olga
    Berger, Thomas
    CNS NEUROSCIENCE & THERAPEUTICS, 2013, 19 (05) : 302 - 306
  • [38] THE EFFECTS OF FAMPRIDINE ON EYE MOVEMENTS IN MULTIPLE SCLEROSIS PATIENTS WITH INTERNUCLEAR OPHTHALMOPLEGIA.
    Kanhai, K.
    Wagenaar, Y. L.
    Bijvank, J. A. Nij
    Klaassen, E. S.
    Lim, K.
    Bergheanu, S. C.
    Petzold, A.
    Verma, A.
    van Rijn, R.
    Groeneveld, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S32 - S33
  • [39] Could Fampridine Attenuate the Severity of COVID-19 in Patients with Multiple Sclerosis?
    Moghadasi, Abdorreza Naser
    Anjidani, Nassim
    Rashvand, Fereshteh
    FRONTIERS IN EMERGENCY MEDICINE, 2021, 5 (03):
  • [40] Lack of Attention to the Administration of Fampridine as a Symptomatic Drug in Iranian Multiple Sclerosis Patients
    Moghadasi, Abdorreza Naser
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2021, 50 (07) : 1513 - 1514
12345